Rgenix to Present Early Clinical Data on RGX-104 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
New York, NY – October 26, 2017 - Rgenix, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule and antibody cancer therapeutics, announced today that Dr. Monica Mita of Cedars-Sinai Medical Center and Principal Investigator of the RGX-104-001 study, will
For Rgenix CEO Masoud Tavazoie, fighting cancer is a family business
Rgenix CEO Masoud Tavazoie was recently interviewed for an article in The Pharma Letter. To read the full piece, please click here. ×
Comments